shutterstock-189768950-web-1

Crystal Eye Studio / Shutterstock.com

10 March 2015Americas

US Supreme Court refuses to hear Tamiflu ‘double patenting’ case

The US Supreme Court yesterday (March 9) refused to hear a case between Californian pharmaceutical company Gilead and India-based Natco that concerns ‘double patenting’.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

‘I’m breaking new ground’: Mölnlycke’s first TM attorney charts a new course

Drug approvals up but global innovation declines

‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute

Preventative IP for preventative pharma healthcare

Court denies Regeneron bid to halt copy of blockbuster eye drug

Interview: Klaus Grabinski, UPC Court of Appeal president

Gilead scores win in fake HIV drug dispute

Polsinelli grows roster with ex-corporate counsel